一种基于二价类细菌颗粒的疫苗在小鼠中诱导了针对苏丹病毒和埃博拉病毒的强效免疫反应。
A Bivalent Bacterium-like Particles-Based Vaccine Induced Potent Immune Responses against the Sudan Virus and Ebola Virus in Mice.
作者信息
Xu Shengnan, Li Wujian, Jiao Cuicui, Cao Zengguo, Wu Fangfang, Yan Feihu, Wang Hualei, Feng Na, Zhao Yongkun, Yang Songtao, Wang Jianzhong, Xia Xianzhu
机构信息
College of Veterinary Medicine, Jilin Agricultural University, Changchun, China.
Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
出版信息
Transbound Emerg Dis. 2023 Apr 24;2023:9248581. doi: 10.1155/2023/9248581. eCollection 2023.
Ebola virus disease (EVD) is an acute viral hemorrhagic fever disease causing thousands of deaths. The large Ebola outbreak in 2014-2016 posed significant threats to global public health, requiring the development of multiple medical measures for disease control. Sudan virus (SUDV) and Zaire virus (EBOV) are responsible for severe disease and occasional deadly outbreaks in West Africa and Middle Africa. This study shows that bivalent bacterium-like particles (BLPs)-based vaccine, SUDV-EBOV BLPs (S/ZBLP + 2 + P), generated by mixing SUDV-BLPs and EBOV-BLPs at a 1 : 1 ratio, is immunogenic in mice. The SUDV-EBOV BLPs induced potent immune responses against SUDV and EBOV and elicited both T-helper 1 (Th1) and T-helper 2 (Th2) immune responses. The results indicated that SUDV-EBOV BLPs-based vaccine has the potential to be a promising candidate against SUDV and EBOV infections and provide a strategy to develop universal vaccines for EVD.
埃博拉病毒病（EVD）是一种急性病毒性出血热疾病，导致数千人死亡。2014 - 2016年的大规模埃博拉疫情对全球公共卫生构成了重大威胁，需要制定多种疾病控制的医学措施。苏丹病毒（SUDV）和扎伊尔病毒（EBOV）是西非和中非严重疾病及偶发致命疫情的病原体。本研究表明，通过将苏丹病毒样颗粒（SUDV - BLPs）和埃博拉病毒样颗粒（EBOV - BLPs）按1∶1比例混合制备的二价类细菌颗粒（BLPs）疫苗，即SUDV - EBOV BLPs（S/ZBLP + 2 + P），在小鼠中具有免疫原性。SUDV - EBOV BLPs诱导了针对SUDV和EBOV的强效免疫反应，并引发了辅助性T细胞1（Th1）和辅助性T细胞2（Th2）免疫反应。结果表明，基于SUDV - EBOV BLPs的疫苗有可能成为预防SUDV和EBOV感染的有前景的候选疫苗，并为开发埃博拉病毒病通用疫苗提供了一种策略。
Zotero 插件